“He cared when no one else did. He not only took the time to figure out what was wrong but listened to what I had to say no matter how crazy I may have sounded. Dr. Templin is a rare type of doctor—he’s the type that clearly loves his career and patients to the core,”…
In an effort to ameliorate serious rheumatology provider shortages, the ACR Workforce Solutions Committee has developed a new resource for primary care providers who treat patients with rheumatic conditions.
Why was this study done? Juvenile dermatomyositis (JDM) is the most common type of idiopathic inflammatory myopathy in childhood, and most patients have a chronic disease course requiring prolonged administration of systemic glucocorticoids and immunosuppressive agents. The initial management for patients with moderately severe JDM is relatively standardized, typically including methotrexate and systemic glucocorticoids with…
It’s an exciting time for ultrasound in rheumatology, & it’s never too late to learn. Whether you’re just starting fellowship or have been practicing for decades, there’s a place for ultrasound in your practice.
The story of one patient whose research participation helped establish VEXAS as a diagnosable condition.
I read a lot of essays and, believe it or not, I’ve been known to write a few on occasion as well. The majority of them kind of linger in the back of my mind and are slowly forgotten. The ones that stick with me tend to be the application essays that I scrutinize every…
Background/Purpose Psoriasis and psoriatic arthritis (PsA) are closely linked inflammatory conditions that can affect both children and adults. In children, these diseases are associated with traditional cardiovascular disease risk factors and subclinical atherosclerosis. In older adults, systemic inflammation from psoriasis and PsA accelerates atherosclerosis, and these conditions are independent risk factors for severe cardiovascular disease…
In this episode, Dr. Bharat Kumar offers some advice to aspiring rheumatologists on how to present themselves in the best light possible in their application essays. He also offers a sneak peek at the rest of the compelling content in the November issue of The Rheumatologist.
Fava et al. investigated longitudinal autoantibody profiles in patients with lupus nephritis (LN) to define serological biomarkers of histologic class. They found that baseline levels of anti-C1q and anti-double-stranded DNA antibodies may serve as noninvasive biomarkers of proliferative LN and anti-C1q antibodies may predict complete response.
An understanding of the mechanisms underlying NET-mediated inflammation will empower clinicians to target therapies that can mitigate disease activity & improve outcomes in patients with lupus.